A photo of Michael J. Rosen.

Medical Director, Schubert-Martin Inflammatory Bowel Disease Center

Associate Director for Faculty Development, Division of Gastroenterology, Hepatology and Nutrition

Associate Professor, UC Department of Pediatrics

513-803-7044

Board Certified

My Biography & Research

Biography

Michael J. Rosen, MD, MSCI, focuses his career on the clinical care of children with inflammatory bowel disease (IBD), and to research aimed at better understanding the causes of chronic inflammation in childhood IBD. Studies from Dr. Rosen’s laboratory have elucidated the role of the type 2 (Th2) immune responses in regulating the intestinal inflammation and predicting response to therapy in pediatric ulcerative colitis. Dr. Rosen also leads an ongoing multi-center study to identify determinants of response to anti-TNF therapy in children hospitalized with acute severe ulcerative colitis.

Dr. Rosen's research has been funded by the National Institutes of Health, the Crohn's & Colitis Foundation, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), and the American College of Gastroenterology. Dr. Rosen serves on the editorial board of the journal Inflammatory Bowel Diseases. He is co-chair of the the Pediatric Affairs Committee for the Crohn's and Colitis Foundation and serves on its National Scientific Advisory Committee. His a past recipient of the NASPGHAN Fellow to Faculty Transition Award in IBD and the George Ferry Young Investigator Award.

Clinical Interests

Pediatric gastroenterology; pediatric inflammatory bowel disease

Research Interests

Mucosal immunology; epithelial biology; clinical pharmacology

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Departments

Gastroenterology GI, Inflammatory Bowel Disease IBD, Autoimmune Liver Disease, Gastroenterology

My Locations

My Education

MD: Harvard Medical School, Boston, MA, 2003.

Residency: Boston Combined Residency Program in Pediatrics (Boston Children's Hospital and Boston Medical Center), Boston, MA, 2003-2006.

Fellowship: Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center and the Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2006-2009.

Masters of Science in Clinical Investigation (MSCI): Vanderbilt University School of Medicine, Nashville, TN, 2009.

Certification: Pediatrics, 2007; Pediatric Gastroenterology, Hepatology and Nutrition, 2009.

My Publications

Development of Infliximab Target Concentrations during Induction in Pediatric Crohn Disease Patients. Clarkston, K; Tsai, YT; Jackson, K; Rosen, MJ; Denson, LA; Minar, P. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:68-74.

Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. Clarkston, K; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA; Minar, P. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:68-74.

Challenges in IBD Research: Preclinical Human IBD Mechanisms. Pizarro, TT; Stappenbeck, TS; Rieder, F; Rosen, MJ; Colombel, J; Donowitz, M; Towne, J; Mazmanian, SK; Faith, JJ; Hodin, RA; et al. Inflammatory Bowel Diseases. 2019; 25:S5-S12.

IL-33 Induces Murine Intestinal Goblet Cell Differentiation Indirectly via Innate Lymphoid Cell IL-13 Secretion. Waddell, A; Vallance, JE; Hummel, A; Alenghat, T; Rosen, MJ. Journal of immunology (Baltimore, Md. : 1950). 2019; 202:598-607.

Contemporary Medical Management of Acute Severe Ulcerative Colitis. Whaley, KG; Rosen, MJ. Inflammatory Bowel Diseases. 2019; 25:56-66.

Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's disease. Kelly, D; Kotliar, M; Woo, V; Jagannathan, S; Whitt, J; Moncivaiz, J; Aronow, BJ; Dubinsky, MC; Hyams, JS; Markowitz, JF; et al. JCI insight. 2018; 3.

Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease. Minar, P; Jackson, K; Tsai, Y; Sucharew, H; Rosen, MJ; Denson, LA. Inflammatory Bowel Diseases. 2018; 24:198-208.

MTG16 is a tumor suppressor in colitis-associated carcinoma. McDonough, EM; Barrett, CW; Parang, B; Mittal, MK; Smith, JJ; Bradley, AM; Choksi, YA; Coburn, LA; Short, SP; Thompson, JJ; et al. JCI insight. 2017; 2.

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. Rosen, MJ; Karns, R; Vallance, JE; Bezold, R; Waddell, A; Collins, MH; Haberman, Y; Minar, P; Baldassano, RN; Hyams, JS; et al. Gastroenterology. 2017; 152:1345-1357.e7.

Activation of TGF-β activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease. Liu, Z; Kong, F; Vallance, JE; Harmel-Laws, E; Amarachintha, S; Steinbrecher, KA; Rosen, MJ; Bhattacharyya, S. Physiological Reports. 2017; 5:e13181-e13181.